nach oben

Erschienen in:

01.06.2019 | Case report

Rivoceranib

Mild hypertension following off-label use: case report

Erschienen in: Reactions Weekly | Ausgabe 1/2019

Einloggen, um Zugang zu erhalten

Excerpt

In a retrospective study involving 6 patients treated between 1 February 2015 and 18 July 2018, a patient [age and sex not stated] was described, who developed grade I hypertension during off-label treatment with rivoceranib for metastatic alveolar soft part sarcoma (ASPS). …

Wang Y, et al. The efficacy and safety of apatinib in metastatic alveolar soft part sarcoma: A case series of six patients in one institution. Cancer Management and Research 11: 3583-3591, Jan 2019. Available from: URL: http://doi.org/10.2147/CMAR.S198429 - ChinaCrossRefPubMedPubMedCentral

Titel: Rivoceranib
Mild hypertension following off-label use: case report
Publikationsdatum: 01.06.2019
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2019
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-019-63856-z

Springer Medizin

Rivoceranib

Mild hypertension following off-label use: case report

Excerpt

Weitere Artikel der Ausgabe 1/2019

Bosentan

Ponatinib

Minocycline

Ibrutinib

Amphotericin B liposomal

Paliperidone

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Bosentan

Ponatinib

Minocycline

Ibrutinib

Amphotericin B liposomal

Paliperidone